[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100350774":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":10,"centralContacts":10,"locations":41,"responsibleParty":47,"collaborators":49,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":75,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Bayer","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"NVAF-patients_1",null,"Adult patients with non-valvular atrial fibrillation (NVAF) and one year health records in the British THIN-database, who have not yet used rivaroxaban, apixaban and warfarin.",[13],"Drug: Rivaroxaban (Xarelto, BAY59-7939)",{"label":15,"type":10,"description":11,"interventionNames":16},"NVAF-patients_2",[17],"Drug: Apixaban (Eliquis)",{"label":19,"type":10,"description":11,"interventionNames":20},"NVAF-patients_3",[21],"Drug: Warfarin",[23,30,35],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Rivaroxaban (Xarelto, BAY59-7939)","Rivaroxaban at a dose of 15 or 20 mg once daily",[9],[29],"Non-Vitamin K Oral Anticoagulant (NOAC)",{"type":24,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Apixaban (Eliquis)","Apixaban at a dose of 2.5 or 5 mg twice daily",[15],[29],{"type":24,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Warfarin","Warfarin dose as prescribed by medical practitioner",[19],[40],"Vitamin K Antagonist",[42],{"facility":43,"status":10,"city":44,"state":10,"zip":10,"country":45,"countryCode":46,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Many facilities","Many Sites","United Kingdom","UK",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[50],{"name":51,"class":6},"Janssen, LP","100350774","study-to-learn-more-about-the-benefits-and-side-effects-of-drugs-rivaroxaban-and-apixaban-compared-to-the-drug-warfarin-for-stroke-prevention-in-patients-with-rapid-and-irregular-heartbeat-which-is-not-due-to-a-heart-valve-fault-non-valvular-atrial-fibrillation-in-the-uk-routine-clinical-practice-100350774",false,"NCT03847181","Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice","Safety and Effectiveness of Rivaroxaban and Apixaban Compared to Warfarin in Non-valvular Atrial Fibrillation Patients in the Routine Clinical Practice in the UK","SiERRA UK","Inclusion Criteria:\n\n* Patients with non-valvular atrial fibrillation\n* New users of rivaroxaban, apixaban or warfarin\n* At least one year enrollment with the general practice (GP)\n* One year since first health contact recorded in THIN prior to the first prescription of a study drug\n\nExclusion Criteria:\n\n* Patients with other recent indications of oral anticoagulant initiation\n* Individuals on more than one oral anticoagulant on the start date\n* Users of rivaroxaban apart from 15 \u002F 20 mg daily dose\n* Users of apixaban apart from 5 \u002F 10 mg daily dose","ALL","18 Years",{"count":63,"type":64},45164,"ACTUAL","OBSERVATIONAL","This population-based study will identify patients with rapid and irregular heartbeat which is not due to a fault with the heart valves (non-valvular atrial fibrillation) who initiate rivaroxaban, apixaban or warfarin as treatment for Stroke Prevention in Atrial Fibrillation (SPAF). Purpose of the study is to learn more about the safety and how well the drugs rivaroxaban, apixaban and warfarin work in patients appropriately and inappropriately receiving standard and reduced doses of each drug for reducing the risk of stroke in atrial fibrillation. Real world data from routine general practice stored in the primary care database in the UK, The Health Improvement Network (THIN), will be used for investigation.",[68],"Atrial Fibrillation",[70,71,72,73,74],"Oral anticoagulants","Under-dosing","Stroke prevention in atrial fibrillation","Safety","Effectiveness","COMPLETED","2021-10-27",{"date":78,"type":64},"2021-10-28",{"date":80,"type":64},"2019-02-28",{"date":82,"type":64},"2020-10-31",{"name":5,"class":6},1]